Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab

Detalles Bibliográficos
Autores principales: Tabarsi, Payam, Afzal, Golnaz, Eskandari, Raha, Dastan, Farzaneh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Research Institute of Tuberculosis and Lung Disease 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978043/
https://www.ncbi.nlm.nih.gov/pubmed/35382084
_version_ 1784680897387167744
author Tabarsi, Payam
Afzal, Golnaz
Eskandari, Raha
Dastan, Farzaneh
author_facet Tabarsi, Payam
Afzal, Golnaz
Eskandari, Raha
Dastan, Farzaneh
author_sort Tabarsi, Payam
collection PubMed
description
format Online
Article
Text
id pubmed-8978043
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher National Research Institute of Tuberculosis and Lung Disease
record_format MEDLINE/PubMed
spelling pubmed-89780432022-04-04 Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab Tabarsi, Payam Afzal, Golnaz Eskandari, Raha Dastan, Farzaneh Tanaffos Letter to the Editor National Research Institute of Tuberculosis and Lung Disease 2021-03 /pmc/articles/PMC8978043/ /pubmed/35382084 Text en Copyright© 2021 National Research Institute of Tuberculosis and Lung Disease https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Letter to the Editor
Tabarsi, Payam
Afzal, Golnaz
Eskandari, Raha
Dastan, Farzaneh
Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
title Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
title_full Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
title_fullStr Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
title_full_unstemmed Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
title_short Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
title_sort late post-coronavirus disease 2019 inflammatory syndrome: a case experience with tocilizumab
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978043/
https://www.ncbi.nlm.nih.gov/pubmed/35382084
work_keys_str_mv AT tabarsipayam latepostcoronavirusdisease2019inflammatorysyndromeacaseexperiencewithtocilizumab
AT afzalgolnaz latepostcoronavirusdisease2019inflammatorysyndromeacaseexperiencewithtocilizumab
AT eskandariraha latepostcoronavirusdisease2019inflammatorysyndromeacaseexperiencewithtocilizumab
AT dastanfarzaneh latepostcoronavirusdisease2019inflammatorysyndromeacaseexperiencewithtocilizumab

Ejemplares similares